NEW YORK, April 10 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (AMEX: MGT), and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, today announced that it has received approval from the Chinese State Food and Drug Administration ("SFDA") for its MedicRead Colon workstation. Medicsight will launch this workstation via a Chinese dealer network which gives the Company access to almost 1000 sales representatives.
David Sumner, Chief Executive of Medicsight, commented: "This is another significant milestone for Medicsight and we are delighted to have received approval from the SFDA. China is one of the world's fastest growing medical imaging markets and is one of Medicsight's core target markets, with a high installed base of MDCT (Multidetector Computed Tomography), high incidence of colorectal cancer and a large population. In anticipation of this approval, Medicsight has been working closely with its Chinese dealer network in preparation for the national launch in Guangzhou during the May Chinese Society of Abdominal Radiology congress."
President Qi Ji, President of the Chinese Society of Radiology, said,
"We have been working with Medicsight for three years as part of their
Chinese clinical program. We have been delighted with the performance of
Medicsight's products, which have proven to make a marked difference in the
speed and accuracy of our diagnosis. As the number of patients in China
increases, CAD software is becoming increasingly important for radiologists
where improved workflow and productivity support their efforts to save
lives. I am delighted that Medicsight'
|SOURCE MGT Capital Investments, Inc.|
Copyright©2008 PR Newswire.
All rights reserved